
-
Erasca NasdaqGS:ERAS Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Location: 3115 Merryfield Row, San Diego, CA, 92121, United States | Website: https://www.erasca.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
110.3M
Cash
304.6M
Avg Qtr Burn
-26.93M
Short % of Float
11.00%
Insider Ownership
12.37%
Institutional Own.
84.48%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Naporafenib (pan-RAF inhibitor) w/ trametinib Details Melanoma, NRASm melanoma | Phase 3 Data readout | |
Naporafenib (pan-RAF inhibitor) w/ trametinib Details Solid tumor/s, RAS Q61X solid tumors | Phase 1b Update | |
ERAS-007 w/ encorafenib and cetuximab Details Cancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer | Phase 1b Update | |
ERAS-801/EGFR inhibitor Details Cancer, Glioblastoma | Phase 1 Data readout | |
ERAS-0015 Details RAS-mutant (RASm) solid tumors | Phase 1 Initiation | |
ERAS-601 (SHP2 inhibitor) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
ERAS-007 Details Non-small cell lung carcinoma | Failed Discontinued | |
ERAS-007 + ERAS-601 Details Solid tumor/s, Cancer | Failed Discontinued |